{
  "query": "aml compliance issues company name",
  "timestamp": "2025-09-06 08:05:39",
  "config": {
    "top_k": 5,
    "similarity_threshold": 0.0,
    "reranking_enabled": true,
    "hybrid_search_enabled": true,
    "hybrid_search_weight": 0.7
  },
  "results": [
    {
      "id": 1,
      "text": "3-1 \nManagement of material topics \np34 AR2023 A committed company / employees \n405-1 \nDiversity of governance bodies and \nemployees \np66 AR2023 Management report / corporate governance statement / diversity, equity and inclusion policy \np194 AR2023 GRI appendix 405-1 / diversity of employees \n405-2 \nRatio of basic salary and remuneration of \nwomen to men \np80 AR2023 Management report / corporate governance statement / codes of \nconduct \nGRI 414 SUPPLIER SOCIAL ASSESSMENT v2016",
      "similarity_score": 0.05429803512716847,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 1070,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 2,
      "text": "ackage or services to a customer which comprises the \nequipment, installation and an agreed number of years of operation and maintenance of the site. The allocation of the price \nto the performance obligations is done based on the standard selling price of each component, driven by budget and taking \ninto accounts some contract negotiation considerations. IBAs contract with the customers typically does not contain \nvariable amounts and the financing component is also considered to be non-significant as milestones payments are spread \nover the project and reflect the progress of IBA in fulfilling its obligations.",
      "similarity_score": 0.06746591345785537,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 726,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 3,
      "text": "inly related to the change of \nworking capital for EUR -16.9 million and the \nnet loss of EUR -9.1 million; Negative financing cash-flow of EUR -14.4 \nmillion \nrelated \nto \nthe \nrepayment \nof \nborrowings and lease liabilities for EUR -7.5 \nmillion (mainly lease liabilities), the dividend \npaid for EUR -6.1 million and; Negative investing cash-flow of EUR -13.3 \nmillion mainly related to acquisitions of \ntangible and intangible assets of EUR -12.3 \nmillion and the convertible loan issued to \nPanTera for EUR -1.0 million. Net financial cash decreased by EUR -49.8 \nmillion from EUR 117.5 million at the end of 2022 \nto EUR 67.7 million at the end of 2023.",
      "similarity_score": 0.06288273362173764,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 522,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 4,
      "text": "onformalFLASH6 technology. This builds on \nthe existing relationship between IBA and \nKUMC, who had previously published a joint \nabstract on FLASH technology together during \nthe \nProton \nTherapy \nCo-Operative \nGroup \n(PTCOG) Congress in June 2023. Earlier in \n2023, IBA also announced the first FLASH \nresearch project on a ProteusONE in a clinical \nsetting, with PARTICLE, the proton therapy \ncenter in Leuven, Belgium. IBA also continues to \ndevelop Proton ARC Therapy and completed a \ncomprehensive integration test at the Proton \nTherapy Center of William Beaumont Hospital in \nMichigan, US, at",
      "similarity_score": 0.06051693840735817,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 199,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    },
    {
      "id": 5,
      "text": "applications, such as food ionization or polymer \ncross-linking. However, IBA is more than ever \nfocused on the medical device sterilization market. Since almost a decade, this market is in a very \nfavorable trend, mainly due to organically increasing \nvolumes and increasing scrutiny and scarcity of the \ntwo dominant established technologies: Gamma and \nethylene oxide. After an exceptional year in 2022, driven by COVID \nimpacts and marked by an increased demand \nfor integrated E-beam and X-ray solutions, the market experienced a soft landing in 2023, requiring IBA to adapt to the evolving landscape.",
      "similarity_score": 0.061391792101241564,
      "metadata": {
        "filename": "annual_report_text (1).txt",
        "filepath": "input\\annual_report_text (1).txt",
        "chunk_id": 25,
        "start_char_idx": 0,
        "end_char_idx": 0,
        "page": null,
        "section": null
      }
    }
  ]
}